Single-particle cryo-electron microscopy (cryo-EM) has recently enabled high-resolution structure determination of numerous biological macromolecular complexes. Despite this progress, the application of high-resolution cryo-EM to G protein coupled receptors (GPCRs) in complex with heterotrimeric G proteins remains challenging, owning to both the relative small size and the limited stability of these assemblies. Here we describe the development of antibody fragments that bind and stabilize GPCR-G protein complexes for the application of high-resolution cryo-EM. One antibody in particular, mAb16, stabilizes GPCR/G-protein complexes by recognizing an interface between Gα and Gβγ subunits in the heterotrimer, and confers resistance to GTPγS-triggered dissociation. The unique recognition mode of this antibody makes it possible to transfer its binding and stabilizing effect to other G-protein subtypes through minimal protein engineering. This antibody fragment is thus a broadly applicable tool for structural studies of GPCR/G-protein complexes.
G-protein coupled receptors (GPCRs) make up the largest receptor family in the human genome, comprising around 800 members. GPCRs are expressed ubiquitously and play essential roles of signal transduction in response to a wide variety of extracellular stimuli such as photons, ions, neurotransmitters, hormones and proteins. Given their numerous physiological roles, GPCRs are implicated in numerous diseases and ~30% of marketed drugs are targeting this receptor family1. Recent advances in GPCR crystallography have led to high-resolution structures of G-protein2 and arrestin3 complexes, which have enhanced our understanding of the structural details underlying ligand binding and signal transduction at the atomic level. The first crystal structure of a GPCR/G-protein complex was that of the β2 adrenergic receptor in complex with stimulatory G-protein, Gs (β2AR/Gs)2. This was later followed by the crystal structure of A2A adenosine receptor in complex with miniGs (A2AR/miniGs) in which a highly engineered Gαs that consists of only the Gα ras-like domain was used in place of the full heterotrimer2,4. The fact that such drastic protein engineering is needed to obtain diffraction quality crystals reflects the difficulty inherent in GPCR–G-protein complex crystallography. Despite the technological advancement, crystallographic studies of these complexes remains extremely difficult. More recently, single-particle cryo-electron microscopy (cryo-EM) has emerged as an alternative technique with the ability to provide near-atomic resolution maps, as demonstrated for two class B GPCRs3,5,6 both in complex with Gs: the glucagon-like peptide1 receptor/Gs (Glp-1R/Gs)6,7 as well as the calcitonin receptor/Gs (CTR/Gs)5. These studies have highlighted the possibility of employing cryo-EM to obtain the structures of GPCR-G protein complexes. Compared to class A GPCRs, class B receptors include a structured extracellular domain that may aid in particle alignment. Furthermore, for Gs proteins, Nb352 stabilizes these complexes against GTPγS by stabilizing an interface between the Ras-like domain of the Gαs subunit and the Gβ subunit. These factors make class B GPCR/Gs protein complexes more tractable targets for cryo-EM compared to class A or other G-protein subtype complexes.
Apart from the GPCR/Gs complex, the only structure available at high-resolution has been limited to the MetaII rhodopsin/GαCt where the last 11-amino-acid fragment of Gtransducin was co-crystalized with the activated rhodopsin8. Although in silico analyses using this complex have provided insights into the conformational changes that allow Gi coupling as well as general principles for G protein coupling specificity9,10, experimental structures of other G-protein complexes are invaluable to understand how receptors selectively engage one G-protein subtype over others. G-protein mimetic nanobodies have been used as a surrogate to capture the active conformation of a receptor11,12,13,14, but it may require an extensive effort to find such nanobodies and the trapped conformation may not necessarily represent the G-protein engaged state.
Here we describe the development of an antibody, termed mAb16, that recognizes the heterotrimeric Gi/o type G protein and enhances the stability of GPCR-Gi/o complexes, while simultaneously adding an asymmetric feature that may aid with cryo-EM particle projection alignment. As antibodies typically bind to their targets in a rigid manner, such an antibody would be expected to enable structure determination of GPCR/G-protein complexes by cryo-EM. mAb16 recognizes a unique epitope, binding at the interface between the α and β subunits of heterotrimeric Gi. While the antibody confers extra stability to GPCR/Gi/o complex as well as increased resistance to GTPγS-triggered dissociation of the complex in a manner similar to Nb35 for Gs, mAb16 and Nb35 bind to completely different epitopes. We have recently succeeded in obtaining a near-atomic resolution map of the mu-opioid receptor (μOR)/Gi complex using this antibody fragment15. Although this antibody is specific against Gi/o-family G-proteins, its ability to bind and stabilize the heterotrimer can be transferred to other G-protein subtypes through a simple protein engineering strategy.
Selection of monoclonal antibodies
Despite exhaustive attempts to crystalize a complex between rhodopsin and heterotrimeric Gi116, we were unsuccessful in producing diffraction quality crystals. We presumed that this was due to the flexibility of the alpha-helical domain of Gαi1 as this domain separates from Ras-like domain and becomes flexible upon receptor-mediated activation in the nucleotide-free state17,18. We then set out to discover antibodies that could reduce this flexibility and facilitate crystallographic and cryo-EM structural studies of the complex. Mice were immunized with purified rhodopsin/Gi1 complex and hybridoma cells were prepared from the isolated mice splenocytes. Clones that showed enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation positive reaction were screened further using an analytical size-exclusion chromatography (SEC) assay with purified monoclonal antibodies. Most of the SEC-positive clones were Gβγ-binders, reflecting that it is the most stable and rigid component of the complex (Fig. 1a, c). Interestingly, we found a single clone that binds and confers GTPγS resistance to the rhodopsin/Gi1 complex (Fig. 1a, b). Based on the clone identification number, we named its antibody mAb16. Notably, this clone does not show binding to any single component of Gi1, but binds specifically to the intact heterotrimeric form of Gi1, suggesting that it binds a composite epitope at the interface between Gαi1 and Gβγ subunits (Fig. 1c). We provide amino-acid sequence of mAb16 in the Supplementary Note 1.
Crystal structure of Gi1/scFv16
In order to better understand the recognition mode of mAb16, we crystallized a fully soluble heterotrimeric Gi1 in complex with mAb16 fragments. We tried both a Fab fragment (Fab16) and single-chain variable fragment (scFv16) derived from mAb16. Both Gi1/Fab16 and Gi1/scFv16 complexes formed crystals but only the scFv16 version diffracted to high resolution, presumably due to the intrinsic flexibility of the linker between the variable and the constant domain of the Fab19. The crystal structure of the Gi1/scFv16 complex was solved at 2.0 Å by molecular replacement using Gi1 (PDB ID: 1GP2) and an scFv fragment (PDB ID: 4NKD) as search models (Table 1). The overall structure of Gi1 in complex with scFv16 is very similar to Gi1 alone (Fig. 2a). The relative position of Ras-like domain and alpha-helical domain of Gαi1 moves closer to Gβ1 by a small rotation movement around the αN-b1 junction (Fig. 2b). This slight movement leads to two additional interactions between Thr182 of Gαi1 and Asn119 of Gβ1, and Arg205 of Gαi1 and Thr143 of Gβ1, located in Switch I and Switch II region, respectively (Fig. 2b). This could be due to the tighter association between these two subunits mediated by scFv16, although it may be the consequence of different crystal contacts between Gi1 alone and Gi1/scFv16. The structure of the Gi1/scFv16 complex shows that scFv16 recognizes an epitope composed of the terminal part of the αN helix of Gαi1 as well as part of the Gβ1 subunit (Fig. 2c, Supplementary Fig. 1). The complementarity-determining region 3 of the heavy chain (CDR-H3) extends to interact with Gβ1 with its tip and Gαi1 with its side. CDR2-H2 and CDR-H1 support the interaction with Gαi1 and Gβ1, respectively by making hydrogen bonds and van der Waals contacts. CDR-L1 is exceptionally long and makes extensive contact with the edge of the αN helix together with CDR-L3 (Fig. 2c). There is no obvious interaction between scFv16 and Gγ2 subunit.
As the α subunits of all Gi/o family members have high sequence similarity at the epitope residues in the αN helix (Fig. 3a) and can form a complex with Gβ1γ2, we expected that Fab16 would bind to all Gi/o family proteins. Using analytical fluorescent SEC, we show that Fab16 can bind to five different Gi/o type G-proteins but not Gs, as it has poor sequence similarity to Gi/o members at this epitope region (Fig. 3b).
Application to other GPCR-Gi/o complexes
Since Fab16 was initially isolated as a stabilizing agent that confers resistance to GTPγS triggered dissociation to a rhodopsin/Gi1 complex and was later found to bind to a panel of Gi/o family members, we investigated whether it confers the same GTPγS resistance to other Gi/o type GPCR complexes. We chose a μ-opioid receptor/Gi1 (μOR/Gi1) and an M2 muscarinic acetylcholine receptor/GoA (M2R/GoA) as representative family A Gi/o-coupling GPCR complexes. Purified μOR/Gi1 or M2R/GoA complex solubilized in detergent was incubated with GTPγS in the presence or absence of Fab16, then analysed for dissociation by analytical SEC. Both μOR/Gi1 and M2R/GoA complexes showed a leftward peak shift upon incubating with Fab16, indicating its binding and also became GTPγS resistant, as they showed much less dissociation in the presence of Fab16 than the complex alone (Fig. 3c). These data with GPCR/Gi/o complexes are consistent with the binding experiments of Fab16 with G-protein alone, and indicate that it stabilizes Gi/o type GPCR complexes in general. In order to show the applicability of scFv16 to structural analysis of GPCR-G protein complexes, we have recently solved a near-atomic resolution map of μOR/Gi1 complex using scFv1615. The presence of scFv16 enhanced complex stability towards specimen vitrification for cryo-EM, thereby enabling quality single-particle reconstructions.
Influence of Fab16 on nucleotide binding
In order to further investigate mAb16 for its protection mechanism against GTPγS, we monitored the binding kinetics of GTPγS to nucleotide-free M2R/GoA complex. In the absence of Fab16, BODIPY-FL-GTPγS, a fluorescent analogue of GTPγS, binds to the complex with fast kinetics reflecting its ability to bind and trigger the dissociation of the complex. In contrast, BODIPY-FL-GTPγS binds to M2R/GoA/Fab16 complex ~70 times slower and to a much lower extent (Fig. 4a). On the other hand, the binding of GDP is only modestly affected when the complex is bound to Fab16 (Fig. 4a). Next we examined the basal nucleotide exchange rate of Gi1 and Gi1/Fab16 under conditions where GDP release is rate-limiting (Fig. 4b). Fab16-bound Gi1 releases GDP ~1.5 to 2-fold slower than Gi1 alone (Table 2). These findings suggest that in the absence of a coupled GPCR, Fab16 stabilizes the heterotrimer in its GDP-bound conformation. As a comparison, we examined the effect of Nb35 that was originally developed against the β2AR/Gs complex2. Structurally, it binds at the interface between switch II and helix III of Gαs and Gβ1, and has been characterized to provide GTPγS resistance to a GPCR/Gs complex. It’s been used for structural studies of all GPCR/Gs-type complexes both in crystallography and cryo-EM so far2,5,6,7. We monitored the binding kinetics of GTPγS and GDP to the nucleotide-free β2AR/Gs complex. BODIPY-FL-GTPγS binds to the complex with fast kinetics in the absence of Nb35 but becomes extremely slow or negligible when bound with Nb35 (Fig. 4c), presumably due to the inhibition of the conformational change in switch II and switch III. BODIPY-FL-GDP showed no detectable binding to the complex alone or to the complex bound with Nb35 (Fig. 4c).
Generalization of mAb16 binding to other G-protein subtypes
Because mAb16’s epitope is located on a short stretch of the αN helix of the Gα subunit (Figs. 2a, b and 3a) as well as a small part of the Gβ1 subunit that can complex with all Gα-protein subtypes, we sought to engineer the αN helix of the other G-protein α-subunits in order to generalize scFv16 binding to all G-protein subtypes. Starting with the Gαs subunit, we generated a chimera in which the αN helix was replaced by the equivalent region of Gαi (GαsiN; residues 1–38 of Gαs replaced by residues 1–31 of Gαi1) (Fig. 5a). The GαsiN protein forms a heterotrimer with the Gβγ subunit and forms a stable complex with the β2AR (Fig. 5b). The β2AR/GsiN complex can bind Fab16 and is largely protected from dissociation induced by GTPγS, whereas β2AR/GsiN complex alone dissociated almost completely under the same condition (Fig. 5b). We then used the same engineering approach to transfer Fab16 binding ability to G11, a Gq family member, and replaced the αN helix of Gα11 with that from Gαi1 (Gα11iN, residues 1–35 of Gα11 replaced by residues 1–29 of Gαi1) (Fig. 5a). The Gα11iN protein forms a heterotrimer with Gβγ subunit and couples to form a stable complex with the M1 muscarinic acetylcholine receptor (M1R) (Fig. 5c). The M1R/G11iN complex alone dissociates upon incubation with GTPγS, whereas the M1R/G11iN complex bound to Fab16 showed GTPγS resistance (Fig. 5c) consistent with Gi/o and GsiN complexes. Negative stain EM visualization of the M1R/G11iN complex reveals a mono-disperse sample (Fig. 5d). These results demonstrate that Fab16 (or scFv16) can be used as a tool with broad variety of GPCR/G-protein complexes by substituting the αN helix of other Gα-subunit with equivalent region of Gαi1. Scanning the chimera junction between Gα11 and Gαi1 shows that a smaller substitution in the middle of the αN helix is still tolerated for the expression and the heterotrimer formation (Supplementary Fig. 2a). When replaced with the equivalent residues with this minimal chimeric region (residues 1–18 of Gαi1), both Gs and G11 are enabled to bind Fab16 and form stable complexes with respective GPCRs (Supplementary Fig. 2b, c.) The same minimal region when transferred to G12 also enables Fab16 binding (Supplementary Fig. 2d). The binding interface of Gβ1 subunit to scFv16 is limited compared to Gα subunit in the crystal structure. These residues are mostly conserved among Gβ family members except Gβ5 (Supplementary Fig. 3). There is no direct interaction between Gγ2 and scFv16 in the crystal structure. The fact that mAb16 was originally raised against and indeed binds to Rhodopsin/Gi1 that is composed of Gγ1 from the native bovine retina and still binds G-proteins or GPCR/G-protein complexes composed of Gγ2 indicates that Fab/scFv16 binds to the heterotrimeric G-protein regardless of the composition of the γ-subunit. Therefore, the binding ability to Fab16 is transferable to broad range of G-protein family members with minimal chimeric constructs. We provide amino-acid sequences of G-protein chimera constructs in the Supplementary Note 2 as well as the primers used for the construction in the Supplementary Table.
In this work, we have developed a unique antibody fragment that recognizes an interface on heterotrimeric Gi1. The antibody confers the GPCR–Gi/o complexes the resistance to GTPγS-induced dissociation. This property is also observed with formerly identified Nb35 for Gs complexes2. Nb35 and mAb16 engage distinct epitopes at the G-protein interface: Nb35 binds at the switch II and αIII helix of Gαs and Gβ, while mAb16 engages the αN helix of Gαi1 and Gβ. The switch II region adopts a distinct conformation upon binding of GTPγS compared to the nucleotide-free or GDP-bound state observed in the crystal structures as well as in the EPR spectroscopic measurement2,20,21,22,23. Nb35 is reported to suppress nucleotide exchange turnover of the CTR/Gs complex5 and indeed it prevents GTPγS binding to the β2AR/Gs complex (Fig. 4c), which we presume due to the fixed conformation of the switch II in the nucleotide-free state and steric clash of the switch III with Nb35. On the other hand, mAb16 binds 40 Å away from the nucleotide-binding pocket with no direct contact with this region yet prevents the binding of GTPγS to the nucleotide-free GPCR/G-protein complex (Fig. 4a) and helps heterotrimeric Gi1 to retain GDP in the nucleotide-binding pocket (Fig. 4b). It has been reported that heterotrimer formation rigidifies the switch II region that is in direct contact with Gβ subunit23. Thus, by stabilizing interactions between the Gβ subunit and switch II, mAb16 prevents GTPγS binding to the empty pocket. This may also explain the slower GDP release as Gβ subunit functions as a GDP dissociation inhibitor (GDI)24. Additional interactions formed between switch I, II and Gβ1 subunit upon scFv16 binding supports this idea (Fig. 2b). Another possibility would be inferred from HDX-MS measurements that revealed the dynamic nature of αN-β1 junction of Gs during the complex formation with β2AR and the dissociation upon addition of GDP/AlF425. Binding of mAb16 would tighten the association of αN helix with Gβ subunit and concomitantly reduce the dynamics of αN–β1 junction, which may influence the binding of nucleotide through the β1-strand and the P-loop that is in direct contact with nucleotide. Previous work showing that binding of GTPγS triggers release of αN helix from Gβ and promotes its unfolding26 indicates that there could be an allosteric effect between the nucleotide-binding pocket and αN helix.
Contrary to the large diversity of different GPCR genes in the human genome, there are only four major G-protein family members: Gs, Gi/o, Gq/11 and G12/1327. Among them Gi/o is the most broadly coupling G-protein10. mAb16 is originally raised against rhodopsin/Gi1 complex and binds rhodopsin/Gi1, μOR/Gi1 and M2R/GoA complexes, suggesting that it likely binds all Gi/o type complexes, according to the sequence similarity of the epitope residues and the binding profile of individual G-protein alone (Fig. 3b). In contrast, the binding interface of Gαs to Nb35 is not conserved among Gα subtypes; therefore it would require elaborate protein engineering to transfer the binding surface to other family members or to evolve the nanobody itself. On the other hand, the binding surface of Gαi1 to mAb16 is located in a small stretch of the αN helix. Since the αN helix apparently serves as a separate module from the Ras-like domain to interact with Gβγ, it is more amenable to generating functional chimeras28,29,30. Previous studies have shown that the entire αN helix of Gαq, Gα12 and Gα13 can be substituted with the corresponding region of Gαi1 to produce functional chimeric Gi/q, Gi/12 and Gi/13. These engineered G proteins retained the biochemical properties of their counterpart wild types, while αN helix of Gα12/13 is reportedly important for the receptor selectivity31. Chimeric Gs protein has also been made with various lengths of αN from Gαi subunit to investigate the functional role of this region32,33. While the chimeras exhibit a large constitutive activity when the substitution goes beyond αN helix to replace the residues 1–62 of Gαs by 1–54 of Gαi, a minor increase in the basal activity was observed when residues 1–41 of Gαs is replaced by 1–34 of Gαi. Our substitutions of GsiN and G11iN are both within the range of these chimeric designs and therefore would be expected to behave in the same way as the wild-type counterparts. In fact, our G protein chimeras form functional heterotrimers with co-expressed Gβγ subunit and form stable and functional complexes with cognate GPCRs. The more conserved chimeras where the residues 1–18 of Gαi1 is transferred to the equivalent residues of Gαs, Gα11 and Gα12 are also able to bind with Fab16 (Supplementary Fig. 2).
In conclusion, the antibody fragment derived from mAb16 promotes the stabilization of GPCR/G-protein complexes and adds an asymmetric feature that may aid with cryo-EM particle projection alignment. The usefulness of the antibody fragment in structural determination was proven by the cryo-EM structure of μOR/Gi1 complex where the presence of scFv16 stabilized the complex for high-resolution cryo-EM work. Furthermore, this antibody fragment can be applied to other G-protein subtypes with minimal protein engineering and therefore would be expected to be a broadly applicable tool for cryo-EM studies of any GPCR/G-protein complex.
Protein expression and purification
Rhodopsin/Gi1 complex was purified as described previously16. Briefly, bovine rhodopsin with three mutations, N2C, M257Y and N282C, was stably expressed in and purified from HEK293S GnTI− cells using 1D4 immunoaffinity chromatography. Purified rhodopsin was incubated with Gi1 reconstituted from recombinant Gαi1 subunit from Escherichia coli BL21 (DE3) cells (Novagen) and Gβγ subunit purified from bovine retina (W L Lawson Company). Rhodopsin/Gi1 complex formation was triggered by the irradiation through 495 nm long-pass filter in the presence of apyrase (Sigma-Aldrich). Rhodopsin/Gi1 complex was separated from the free rhodopsin or Gi1 by SEC on a Tricorn 10/600 column packed with Superdex 200 (GE healthcare) in a buffer containing 100 mM NaCl, 20 mM Hepes pH 7.5, 0.01% lauryl maltose neopentyl glycol (MNG), 2 mM 2-mercaptoethanol.
µOR with a cleavable amino and carboxy-terminal FLAG- and His-tag13 was expressed in Spodoptera frugiperda Sf9 insect cells using baculovirus infection system (Expression Systems). Cells were solubilized in 1% n-dodecyl-β-d-maltoside (DDM) (Anatrace), 0.2% 5-cholesterol hemisuccinate (CHS) (Steraloids) and the soluble fraction was purified by Ni-chelating sepharose chromatography. The eluted protein was supplemented with 2 mM CaCl2, loaded onto M1 anti-FLAG immunoaffinity column (prepared in house) and washed with progressively lower concentrations of the antagonist naloxone (Sigma-Aldrich). Receptor was eluted in a buffer consisting of 100 mM NaCl, 20 mM Hepes pH 7.5, 0.1% DDM, 0.01% CHS with 50 nM naloxone, and further purified by SEC on a Superdex 200 10/300 column in a buffer containing 1 µM lofentanil (Tronto Research Chemicals) to exchange the ligand. Monomeric fractions were pooled, further supplemented with a twofold molar excess of lofentanil and concentrated to ~100 µM for complex formation.
β2AR was purified in the same way as described previously34. Briefly, Sf9 insect cells were lysed by osmotic shock prior to solubilization of the membrane fraction by DDM. Solubilized receptor was first purified by M1 anti-FLAG immunoaffinity chromatography, followed by alprenolol-sepharose chromatograpy (alprenolol-sepharose resin prepared in house) to isolate only functional receptor. Alprenolol-sepharose eluate was concentrated on M1 FLAG affinity resin, and then washed with ligand-free buffer for 1 h at room temperature to eliminate bound alprenolol. Receptor was eluted in a buffer consisting of 20 mM Hepes pH 7.5, 350 mM NaCl, 0.1 % DDM and 0.01% CHS and further purified by size-exclusion chromatography on a Superdex 200 10/300 column (GE Healthcare) in buffer containing 20 mM Hepes pH 7.5, 100 mM NaCl, 0.05 % DDM, 0.005% CHS and 1 µM BI-167107 (Boehringer-Ingelheim). The eluated receptor was concentrated to ~100 µM for complexing.
For M1R and M2R, we used constructs used in previous studies12,35 with some modifications. Briefly, T4L in the ICL3 of M1R was removed, and residues 219–232 and 345–354 were added to TM5 and TM6, respectively. The ICL3 of M2R was extended by 15 amino-acid residues from TM6. Primer sequences for these modifications are provided in the Supplementary Table. The amino-acid sequences for these receptors are provided in the Supplementary Note 2. These receptors were purified essentially in the same way as µOR with detergent exchange to MNG during M1 FLAG chromatography and using atropine (Sigma-Aldrich) and iperoxo (Sigma-Aldrich) in place of naloxone and lofentanil, respectively.
Heterotrimeric G-proteins were expressed and purified as previously described. Briefly, Trichuplusia ni (Hi5) insect cells (Expression Systems) were co-infected with two viruses, one encoding the wild-type human Gα subunit and another encoding the wild-type human β1γ2 subunits with an decahistidine tag inserted at the amino terminus of the β1 subunit with HRV-3C protease cleavable site. In the case of G11iN, additional virus encoding Ric8A was also co-infected. Cells were harvested 48 h post infection, lysed in hypotonic buffer and lipid-modified heterotrimeric G-protein was extracted in a buffer containing 1% sodium cholate (Sigma-Aldrich) and 0.05% DDM. The soluble fraction was purified using Ni-chelating sepharose chromatography, and the detergent was exchanged from cholate/DDM mixture to DDM alone. After elution, HRV-3C protease (in-house prepared) was added and the protein was dialyzed against a buffer containing 20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 0.05% DDM, 100 μM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (Sigma-Aldrich), 10 μM GDP (Sigma-Aldrich). Cleaved heterotrimeric G-protein was further purified by reloading over Ni-sepharose resin. The flow through was collected and purified over a size-exclusion chromatography using a Superdex 200 10/300 column.
Soluble Gβγ subunit for crystallography was expressed and purified from Trichuplusia ni (Hi5) insect cells. Hi5 cells were infected with baculovirus encoding the human β1γ2 subunits with cysteine 68 of γ2 subunit mutated to serine (Gβ1γ2C68S) to remove the geranylgeranylation modification. A decahistidine tag was attached at the amino terminus of the β1 subunit with HRV-3C protease cleavable site. Cultures were harvested 48 h post infection. Cells were lysed in the lysis buffer (10 mM Tris pH 7.4, 5 mM 2-mercaptoethanol, 160 μg/mL benzamidine and 2.5 μg/mL leupeptin). Following to the centrifugation, the supernatant was incubated with Ni-chelating sepharose. The resin was first washed with a high salt buffer (20 mM Hepes pH 7.5, 500 mM NaCl, 20 mM imidazole and 2 mM 2-mercaptoethanol) then a low salt buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 20 mM imidazole and 100 μM TCEP). The protein was eluted with an elution buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 250 mM imidazole and 100 μM TCEP) and dialysed against 20 mM Hepes pH 7.5, 100 mM NaCl and 100 μM TCEP after adding HRC-3C protease to cleave amino-terminal His-tag. Gβ1γ2C68S was further purified by reloading over Ni-sepharose resin. The flow through was collected and purified by a size-exclusion chromatography using a Superdex 200 10/300 column.
The human Gαi1 protein for crystallography was expressed in Escherichia coli Rosetta2 (DE3) cells (Novagen) with an N-terminal octahistidine-tag and an HRV-3C protease recognition site. The culture was grown at 37 °C in TB medium. When the OD 600 reached 0.6, the protein expression was induced with 0.5 mM IPTG and further grown for 20 h at 24 °C. The cells were harvested by centrifugation, resuspended in the lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM imidazole, 0.1 mM PMSF, 10 μM GDP and 5 mM 2-mercaptoethanol). The resuspended cells were disrupted by sonication. Cell lysate was clarified by centrifugation and the supernatant was incubated with Ni-chelating sepharose equilibrated with the lysis buffer. The resin was first washed with the high salt buffer (20 mM Hepes pH 7.5, 500 mM NaCl, 1 mM MgCl2, 20 mM imidazole, 10 μM GDP and 2 mM 2-mercaptoethanol) then the low salt buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 20 mM imidazole, 10 μM GDP and 100 μM TCEP). The protein was eluted with the elution buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 250 mM imidazole, 10 μM GDP and 100 μM TCEP) and dialysed against 20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 10 μM GDP and 100 μM TCEP after adding HRC-3C protease to cleave amino-terminal tag. Cleaved Gαi1 was further purified by reloading over Ni-sepharose resin. The flow through was collected and purified over a size-exclusion chromatography using a Superdex 200 10/300 column.
GPCR/G-protein complex was prepared essentially in the same way as described previously using agonists lofentanil, iperoxo, BI-167107 for μOR, M1R and M2R, β2AR, respectively2. Briefly, receptor was mixed with 1.2–1.5 molar excess G-protein. Following the incubation at room temperature for 1 h, apyrase was added and the reaction mixture was transferred to 4 °C and further incubated for 4 h to overnight. Prior to loading M1 FLAG column, 1% MNG and 0.1% CHS was added. The MNG concentration was progressively lowered during M1 FLAG wash. FLAG eluted protein was further purified by size-exclusion chromatography on a Superdex 200 10/300 column.
Monoclonal antibody production and characterization
For the antigen, rhodopsin–Gi1 complex was stabilized by crosslink using BS-3 (ThermoFisher). Naval Medical Research Institute (NMRI) mice were immunized intraperitoneally with the emulsified antigen. (This study was carried out in strict accordance with the Rules and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the Swiss Bundesamt für Veterinärwesen. The protocol was ethically approved by the Ethikkommission beider Basel (Permit Number: 237/23523).) Mice with strong ELISA reaction to the antigen were killed and the spleen was removed. Isolated splenocytes were fused with the myeloma cell partner (PAI mouse myeloma cells, derived from P3-x63-AG8) using polyethylene glycol 1500 (Roche Diagnostics). The fusion mixture was plated into multi-well plates (Thermo Scientific Nunc MicroWell Cell Culture High Flange 96-Well Microplates) and clonal hybridomas were selected by growing in HAT medium supplemented with culture supernatant of mouse macrophages P388. IgG positive clones were screened by ELISA for reactivity against Rhodopsin/Gi1 complex. Clones that showed a positive reaction in an ELISA assay and by immunoprecipitation were further characterized as monoclonal antibodies or Fab fragments. Initial SEC analysis using rhodopsin/Gi1 or each component was carried out in 20 mM Hepes pH 7.5, 100 mM NaCl, 2 mM 2-mercaptethanol and 0.01% MNG using Superdex 200 10/200 column.
Coding regions of the heavy-chain (VH-CH1) and light-chain (VL-CL) of mAb16 were cloned into the modified pVL1392 vector where VH-CH1 and VL-CL both attached with GP67 secretion signal sequence were under polyhedron and p10 promoter regulation, respectively. Octahistidine-tag with HRV-3C protease cleavable site was attached to the carboxy-terminus of VH-CH1 for the purification. The single-chain variable fragment of mAb16 (scFv16) was cloned into a modified pVL1392 vector containing a GP67 secretion signal immediately prior to the amino terminus of the scFv16. Octahistidine-tag with HRV-3C protease cleavable site was attached to the carboxy-terminus.
Both Fab16 and scFv16 were expressed in secreted form from Trichuplusia ni Hi5 insect cells using the baculovirus infection method (Expression Systems), and purified by Ni-sepharose chromatography. Supernatant from baculovirus infected cells was pH balanced by addition of Tris pH 7.5. Chelating agents were quenched by addition of 1 mM nickel chloride and 5 mM calcium chloride and incubation with stirring for 1 h at 25 °C. Resulting precipitates were removed by centrifugation and the supernatant was loaded over Ni-sepharose chromatography column. The column was washed with a high salt buffer (20 mM Hepes pH 7.5, 500 mM NaCl and 20 mM imidazole) followed by a low salt buffer (20 mM Hepes pH 7.5, 100 mM NaCl and 20 mM imidazole). The protein was eluted with the elution buffer (20 mM Hepes pH 7.5, 100 mM NaCl and 250 mM imidazole) and the carboxy-terminal octahistidine tag was cleaved by incubation with HRV-3C protease during dialysis against a buffer consisting of 20 mM Hepes pH 7.5 and 100 mM NaCl. Cleaved protein was further purified by reloading over Ni-NTA resin. The flow through was collected and purified over a size-exclusion chromatography using a Superdex 200 16/60 column (GE healthcare). Monomeric fractions were pooled, concentrated and flash frozen in liquid nitrogen until use.
For the binding assay of Fab16 with heterotrimeric G-protein subtypes, Fab16 was first labelled with Alexa Fluor 488 NHS Ester (ThermoFisher Scientific) in 20 mM MES pH 6.5. Free dye was removed by G-50 desalting column (GE healthcare), and the labelled Fab16 was recovered and concentrated. 5–30 μM of G-protein was mixed with 0.4 μM of labelled Fab16, incubated for 1 h and run on SEC on a Superdex 200 10/300 column. Fluorescence signal was recorded with excitation at 488 nm and emission at 512 nm.
Construction of chimeric G proteins
GαsiN was constructed by substituting the residues 1–38 of Gαs with the residues 1–31 of Gαi1. Gα11iN were constructed by substituting the residues 1–36 of Gα11 with the residues 1–29 of Gαi1. These constructs were cloned into pFastBac1 vector and baculovirus were made according to the manufacturer. Scanning chimeras of Gα11 as well as GαsiN18, Gα11iN18 and Gα12iN18 are also made in the same way. Primer sequences used to construct the chimeras are provided in the Supplementary Table. The amino-acid sequences of the chimera constructs are provided in the Supplementary Note 2.
Characterizing resistance to GTPγS
GTPγS resistance test was performed in the buffer containing 20 mM Hepes pH7.5, 100 mM NaCl, 100 μM TCEP, 0.01% MNG, with each agonist for the complex, lofentanil, iperoxo, BI167107 for μOR/Gi1, M1R/G11iN and M2R/GoA, β2AR/GsiN, respectively. Purified complex with or without Fab16 was incubated with 100 μM GTPγS in the buffer and incubated for 1 h at 24 °C followed by SEC analysis on Superdex 200 10/300 monitoring the protein intrinsic fluorescence with the excitation wavelength at 280 nm and emission wavelength 340 nm.
Determination of the structure of the Gi1/scFv16 complex
For Gi1/scFv16 crystallization, separately purified and concentrated Gαi1, Gβ1γ2C68S and scFv16 were mixed at a 1:1:1.2 molar ratio and incubated for 30 min at 24 °C. The resulting Gi1/scFv16 complex was purified from uncomplexed subunits and free scFv16 by SEC in the buffer containing 20 mM Hepes pH7.5, 100 mM NaCl, 1 mM MgCl2, 10 μM GDP and 100 μM TCEP. Purified Gi1/scFv16 was incubated with 1 mM aluminium chloride and 50 mM sodium fluoride for 1 h on ice, concentrated to 10–15 mg/mL and crystallized using the hanging drop vapour diffusion method at 20 °C against a reservoir solution containing 10% PEG 8000, 0.1 M Sodium citrate pH 5.0, 1 mM MgCl2, 10 μM GDP, 100 μM TCEP, 1 mM aluminium chloride and 10 mM sodium fluoride. Crystals appeared within a few hours and grew to the full size in 5 days. Crystals were soaked into the reservoir solution supplemented with 25% glycerol as a cryo-protectant and flash frozen in liquid nitrogen. The X-ray data set was collected at the experimental station 12-2 in the Stanford Synchrotron Radiation Lightsource. Diffraction data were integrated by XDS36, scaled and merged by AIMLESS37. The structure was solved by the molecular replacement in Phaser38 using the heterotrimeric Gi-protein (1GP2) and scFv fragment (4NKD) as independent search models. Manual model building was performed in Coot39 and refinement was performed with Phenix refine40,41. Ramachandran statistics are favoured 96.6%, allowed 3.4%, outlier 0.0%.
For the nucleotide-binding experiment, fluorescence from BODIPY-FL-GTPγS or BODIPY-FL-GDP (ThermoFisher Scientific) was recorded using the Fluorolog spectrophotometer (HORIBA) in the 500 μL quartz cuvette. The fluorophore was exited at 495 nm and emission was detected at 508 nm at 22 °C. The buffer composition is 20 mM HEPES, pH 7.5, 100 mM sodium chloride, 0.01% LMNG, 10 mM magnesium chloride, 100 μM TCEP and 10 μM iperoxo or BI-167107 for GPCR/G-protein complexes, and 20 mM HEPES, pH 7.5, 100 mM sodium chloride, 0.02% DDM, 10 mM magnesium chloride, 100 μM TCEP for Gi1. Kinetics data were collected with 1 μM fluorophore alone for 100 s to establish the baseline fluorescence intensity. Protein was added to 200 nM and rapidly mixed in the fluorescence cuvette. Data points were acquired every second for 600 s. The resulting kinetics spectra were plotted and fit to one phase- or two phase-association function using GraphPad Prism 7.0.
Data supporting the findings of this manuscript are available from the corresponding authors upon reasonable request. Structure and data set in this work have been deposited in the Protein Data Bank under accession code PDB 6CRK.
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug. Discov. 16, 829 EP (2017).
Rasmussen, S. G. F. et al. Crystal structure of the [bgr]2 adrenergic receptor-Gs protein complex. Nature 477, 549–555 (2011).
Kang, Y. et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523, 561–567 (2015).
Carpenter, B., Nehmé, R., Warne, T., Leslie, A. G. W. & Tate, C. G. Structure of the adenosine A(2A) receptor bound to an engineered G protein. Nature 536, 104–107 (2016).
Liang, Y.-L. et al. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature 546, 118–123 (2017).
Zhang, Y. et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546, 248–253 (2017).
Liang, Y.-L. et al. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. Nature 555, 121–125 (2018).
Choe, H.-W. et al. Crystal structure of metarhodopsin II. Nature 471, 651–655 (2011).
Rose, A. S. et al. Position of transmembrane helix 6 determines receptor g protein coupling specificity. J. Am. Chem. Soc. 136, 11244–11247 (2014).
Flock, T. et al. Selectivity determinants of GPCR-G-protein binding. Nature 545, 317–322 (2017).
Rasmussen, S. G. F. et al. Structure of a nanobody-stabilized active state of the [bgr]2 adrenoceptor. Nature 469, 175–180 (2011).
Kruse, A. C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 1998–2003 (2013).
Huang, W. et al. Structural insights into µ-opioid receptor activation. Nature 524, 315–321 (2015).
Che, T. et al. Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell 172, 55–67.e15 (2018).
Koehl, A. et al. Structure of the µ-opioid receptor-Gi protein complex. Nature 558, 547–552 (2018).
Maeda, S. et al. Crystallization scale preparation of a stable GPCR signaling complex between constitutively active rhodopsin and G-protein. PLoS ONE 9, e98714 (2014).
Van Eps, N. et al. Interaction of a G protein with an activated receptor opens the interdomain interface in the alpha subunit. Proc. Natl Acad. Sci. USA 108, 9420–9424 (2011).
Westfield, G. H. et al. Structural flexibility of the G s -helical domain in the 2-adrenoceptor Gs complex. Proc. Natl Acad. Sci. USA 108, 16086–16091 (2011).
Stura, E. A., Fieser, G. G. & Wilson, I. A. Crystallization of antibodies and antibody-antigen complexes. Immunomethods 3, 164–179 (1993).
Sunahara, R. K. Crystal structure of the adenylyl cyclase activator Gs. Science 278, 1943–1947 (1997).
Mixon, M. B. et al. Tertiary and quaternary structural changes in gialpha induced by GTP hydrolysis. Science 270, 954–960 (1995).
Coleman, D. et al. Structures of active conformations of Gi alpha 1 and the mechanism of GTP hydrolysis. Science 265, 1405–1412 (1994).
Van Eps, N., Oldham, W. M., Hamm, H. E. & Hubbell, W. L. Structural and dynamical changes in an -subunit of a heterotrimeric G protein along the activation pathway. Proc. Natl Acad. Sci. USA 103, 16194–16199 (2006).
Brandt, D. R. & Ross, E. M. GTPase activity of the stimulatory GTP-binding regulatory protein of adenylate cyclase, Gs. Accumulation and turnover of enzyme-nucleotide intermediates. J. Biol. Chem. 260, 266–272 (1985).
Chung, K. Y. et al. Conformational changes in the G protein Gs induced by the [bgr]2 adrenergic receptor. Nature 477, 611–615 (2011).
Medkova, M., Preininger, A. M., Yu, N.-J., Hubbell, W. L. & Hamm, H. E. Conformational changes in the amino-terminal helix of the G protein alpha(i1) following dissociation from Gbetagamma subunit and activation. Biochemistry 41, 9962–9972 (2002).
Downes, G. B. & Gautam, N. The G protein subunit gene families. Genomics 62, 544–552 (1999).
Tesmer, V. M., Kawano, T., Shankaranarayanan, A., Kozasa, T. & Tesmer, J. J. G. Snapshot of activated G proteins at the membrane: the Galphaq-GRK2-Gbetagamma complex. Science 310, 1686–1690 (2005).
Kreutz, B. et al. A new approach to producing functional gα subunits yields the activated and deactivated structures of Gα 12/13proteins. Biochemistry 45, 167–174 (2006).
Nishimura, A. et al. Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule. Proc. Natl Acad. Sci. USA 107, 13666–13671 (2010).
Yamaguchi, Y., Katoh, H. & Negishi, M. N-terminal short sequences of alpha subunits of the G12 family determine selective coupling to receptors. J. Biol. Chem. 278, 14936–14939 (2003).
Osawa, S., Dhanasekaran, N., Woon, C. W. & Johnson, G. L. G alpha i-G alpha s chimeras define the function of alpha chain domains in control of G protein activation and beta gamma subunit complex interactions. Cell 63, 697–706 (1990).
Russell, M. & Johnson, G. L. G protein amino-terminal alpha i2/alpha s chimeras reveal amino acids important in regulating alpha s activity. Mol. Pharmacol. 44, 255–263 (1993).
Gregorio, G. G. et al. Single-molecule analysis of ligand efficacy in β2AR-G-protein activation. Nature 547, 68–73 (2017).
Thal, D. M. et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531, 7282–7287 (2016).
Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 (2006).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352–367 (2012).
Flock, T. et al. Universal allosteric mechanism for Gα activation by GPCRs. Nature 524, 173–179 (2015).
We thank Jean-Philippe Carralot (F. Hoffmann-La Roche Ltd) for help in antibody generation, Martin Siegrist, Georg Schmid, Bernard Rutten, Doris Zulauf, Stephanie Kueng (Roche Non-Clinical Biorepository) and Ralf Thoma for technical assistance for biomass and cell line generation. Shoji Maeda was supported by the Roche Postdoctoral Fellowship (RPF ID: 113). This work was supported by NIH grant R01GM083118 to B.K.K. B.K.K. is a Chan Zuckerberg Biohub investigator.
B.K.K. is a co-founder of and consultant for ConfometRx. R.J.P.D. is employed by Roche Pharmaceuticals. The remaining authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Maeda, S., Koehl, A., Matile, H. et al. Development of an antibody fragment that stabilizes GPCR/G-protein complexes. Nat Commun 9, 3712 (2018). https://doi.org/10.1038/s41467-018-06002-w
Nature Structural & Molecular Biology (2022)
Nature Communications (2022)
Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139
Cell Research (2022)
Nature Chemical Biology (2021)